Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White Syndrome
Identifieur interne : 000589 ( Main/Curation ); précédent : 000588; suivant : 000590Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White Syndrome
Auteurs : W. Shimizu [Japon] ; T. Ohe [Japon] ; T. Kurita [Japon] ; H. Takaki [Japon] ; N. Aihara [Japon] ; S. Kamakura [Japon] ; M. Matsuhisa [Japon] ; K. Shimomura [Japon]Source :
- European Heart Journal [ 0195-668X ] ; 1992-02.
Abstract
In order to evaluate the electrophysiological effects of the combined administration of disopyramide and mexiletine on anterograde accessory pathway conduction, we studied 11 patients with Wolff-Parkinson- White (WPW) syndrome. Disopyramide was first infused intravenously at 1 mg kg−1for 5 min followed by a continuous infusion at 0.025 mg kg−1 min−1. After the infusion rate of disopyramide was decreased to 0.004 mg kg−1 mm−1 to maintain a lower serum concentration, mexiletine was infused at 2mg kg−1 for 5 min followed by a continuous infusion at 0.008mg kg−1 min−1 (protocol 1). The shortest atrial paced cycle length with 1:1 anterograde accessory pathway conduction (shortest CL with 1:1) and the anterograde effective refractory period of the accessory pathway (ERP) were measured: (1) before drug administration, (2) after disopyramide was given alone, and (3) after disopyramide and mexiletine were combined at lower concentrations. The same protocol was repeated with the order of drug administration reversed (mexiletine followed by disopyramide) in all patients (protocol 2). Both disopyramide and mexiletine lengthened the shortest CL with 1:1 and the ERP to the same degree. The combination of disopyramide and mexiletine at lower concentrations further lengthened the shortest CL with 1:1. It was longer than with disopyramide (protocol 1) or mexiletine (protocol 2) alone [protocol 1. 412 ± 169 ms (combination) vs 356 ± 117 ms (disopyramide); P <0.05, protocol 2: 409 ± 166 ms (combination) vs 355 . 119 ms (mexiletine); P <0.01]. The combination lengthened the ERP more than did mexiletine alone [332 ± 73 ms (combination) vs 299 ± 42 ms (mexiletine): p <0.05]. Moreover, it lengthened the shortest and the mean RR interval during atrial fibrillation more than disopyramide or mexiletine did alone in alifour patients in whom atrial fibrillation was induced. We conclude that a combination of disopyramide and mexiletine has at least additive effects on anterograde accessory pathway conduction in patients with WPW syndrome.
Url:
DOI: 10.1093/oxfordjournals.eurheartj.a060157
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000674
Links to Exploration step
ISTEX:CEA1C94184B83D23F8CE5FD0B017828A66AC0261Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White Syndrome</title><author><name sortKey="Shimizu, W" sort="Shimizu, W" uniqKey="Shimizu W" first="W." last="Shimizu">W. Shimizu</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Ohe, T" sort="Ohe, T" uniqKey="Ohe T" first="T." last="Ohe">T. Ohe</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Kurita, T" sort="Kurita, T" uniqKey="Kurita T" first="T." last="Kurita">T. Kurita</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Takaki, H" sort="Takaki, H" uniqKey="Takaki H" first="H." last="Takaki">H. Takaki</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Aihara, N" sort="Aihara, N" uniqKey="Aihara N" first="N." last="Aihara">N. Aihara</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Kamakura, S" sort="Kamakura, S" uniqKey="Kamakura S" first="S." last="Kamakura">S. Kamakura</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Matsuhisa, M" sort="Matsuhisa, M" uniqKey="Matsuhisa M" first="M." last="Matsuhisa">M. Matsuhisa</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Shimomura, K" sort="Shimomura, K" uniqKey="Shimomura K" first="K." last="Shimomura">K. Shimomura</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CEA1C94184B83D23F8CE5FD0B017828A66AC0261</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1093/oxfordjournals.eurheartj.a060157</idno><idno type="url">https://api.istex.fr/document/CEA1C94184B83D23F8CE5FD0B017828A66AC0261/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000674</idno><idno type="wicri:Area/Main/Curation">000589</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White Syndrome</title><author><name sortKey="Shimizu, W" sort="Shimizu, W" uniqKey="Shimizu W" first="W." last="Shimizu">W. Shimizu</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Ohe, T" sort="Ohe, T" uniqKey="Ohe T" first="T." last="Ohe">T. Ohe</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Kurita, T" sort="Kurita, T" uniqKey="Kurita T" first="T." last="Kurita">T. Kurita</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Takaki, H" sort="Takaki, H" uniqKey="Takaki H" first="H." last="Takaki">H. Takaki</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Aihara, N" sort="Aihara, N" uniqKey="Aihara N" first="N." last="Aihara">N. Aihara</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Kamakura, S" sort="Kamakura, S" uniqKey="Kamakura S" first="S." last="Kamakura">S. Kamakura</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Matsuhisa, M" sort="Matsuhisa, M" uniqKey="Matsuhisa M" first="M." last="Matsuhisa">M. Matsuhisa</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author><author><name sortKey="Shimomura, K" sort="Shimomura, K" uniqKey="Shimomura K" first="K." last="Shimomura">K. Shimomura</name><affiliation wicri:level="1"><mods:affiliation>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka, Japan</mods:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Cardiology Division of Medicine. National Cardiovascular Center, Suita, Osaka</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">European Heart Journal</title><idno type="ISSN">0195-668X</idno><idno type="eISSN">1522-9645</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1992-02">1992-02</date><biblScope unit="volume">13</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="261">261</biblScope><biblScope unit="page" to="268">268</biblScope></imprint><idno type="ISSN">0195-668X</idno></series><idno type="istex">CEA1C94184B83D23F8CE5FD0B017828A66AC0261</idno><idno type="DOI">10.1093/oxfordjournals.eurheartj.a060157</idno><idno type="ArticleID">13.2.261</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0195-668X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">In order to evaluate the electrophysiological effects of the combined administration of disopyramide and mexiletine on anterograde accessory pathway conduction, we studied 11 patients with Wolff-Parkinson- White (WPW) syndrome. Disopyramide was first infused intravenously at 1 mg kg−1for 5 min followed by a continuous infusion at 0.025 mg kg−1 min−1. After the infusion rate of disopyramide was decreased to 0.004 mg kg−1 mm−1 to maintain a lower serum concentration, mexiletine was infused at 2mg kg−1 for 5 min followed by a continuous infusion at 0.008mg kg−1 min−1 (protocol 1). The shortest atrial paced cycle length with 1:1 anterograde accessory pathway conduction (shortest CL with 1:1) and the anterograde effective refractory period of the accessory pathway (ERP) were measured: (1) before drug administration, (2) after disopyramide was given alone, and (3) after disopyramide and mexiletine were combined at lower concentrations. The same protocol was repeated with the order of drug administration reversed (mexiletine followed by disopyramide) in all patients (protocol 2). Both disopyramide and mexiletine lengthened the shortest CL with 1:1 and the ERP to the same degree. The combination of disopyramide and mexiletine at lower concentrations further lengthened the shortest CL with 1:1. It was longer than with disopyramide (protocol 1) or mexiletine (protocol 2) alone [protocol 1. 412 ± 169 ms (combination) vs 356 ± 117 ms (disopyramide); P <0.05, protocol 2: 409 ± 166 ms (combination) vs 355 . 119 ms (mexiletine); P <0.01]. The combination lengthened the ERP more than did mexiletine alone [332 ± 73 ms (combination) vs 299 ± 42 ms (mexiletine): p <0.05]. Moreover, it lengthened the shortest and the mean RR interval during atrial fibrillation more than disopyramide or mexiletine did alone in alifour patients in whom atrial fibrillation was induced. We conclude that a combination of disopyramide and mexiletine has at least additive effects on anterograde accessory pathway conduction in patients with WPW syndrome.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000589 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000589 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:CEA1C94184B83D23F8CE5FD0B017828A66AC0261
|texte= Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White Syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |